Buy VSTM by Oct 2, 2026.

Verastem(VSTM) has a phase 2 trial [fastracked by the FDA](https://www.pharmacytimes.com/view/fda-grants-fast-track-designation-to-vs-7375-for-kras-g12d-mutated-advanced-nsclc) of VS-7375 aimed at pancreatic, lung and colorectal cancer. As stated in their last earnings report ["we look forward to sharing additional clinical data in October"](https://investor.verastem.com/node/16096/pdf), so next month can be a good catalyst, also just today they announced that they will be in a healthcare conference on september 8, another one on september 10, and an investment conference on september 14. You don't line up 3 conferences the month …